NCT06923228View on ClinicalTrials.gov

A Study to Assess Efficacy and Safety of CGB-500, 1% Tofacitinib Versus an Active Comparator for Atopic Dermatitis

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

April 21, 2025

Primary Completion Date

July 30, 2025

Study Completion Date

September 30, 2025

Conditions
Atopic Dermatitis (AD)
Interventions
DRUG

CGB-500 Ointment with 1% tofacitinib

experimental drug

DRUG

Ruxolitinib 1.5% Cream QD

topical cream

Sponsors

Lead Sponsor

CAGE Bio Inc.
All Listed Sponsors
lead

CAGE Bio Inc.

INDUSTRY

NCT06923228 - A Study to Assess Efficacy and Safety of CGB-500, 1% Tofacitinib Versus an Active Comparator for Atopic Dermatitis | Biotech Hunter | Biotech Hunter